Day: November 2, 2023

Orlando, FL, Nov. 02, 2023 (GLOBE NEWSWIRE) — Biostax Corp (OTC Pink: BTAX) (“Biostax”), a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of Directors. Ms. Caperton stands as the esteemed founder and CEO of BOSACS Holding, LLC, boasting a rich history in the dynamic realm of sports management and has maintained a fervent dedication to the not-for-profit sector spanning over two decades. Her impactful journey has seen her contribute significantly to esteemed organizations, including the Bon Secours Foundation Board, Trinity Episcopal School Board of Trustees, Boys & Girls Clubs of Richmond, St. Mary’s Episcopal School Board of Trustees, Soar365, and United Way Services of Greater Richmond. In her remarkable career, Ms. Caperton has demonstrated exceptional prowess as a...

MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology (ASN) Kidney Week in Philadelphia today. These data, presented in a poster titled “Control of Secondary Hyperparathyroidism with Extended-release Calcifediol is Associated with Slower CKD Progression” (#TH-PO1152), indicate that early, sustained and effective treatment of secondary hyperparathyroidism (SHPT) with RAYALDEE is associated with significantly slower progression of chronic kidney disease (CKD) in pre-dialysis patients. The poster is available on OPKO’s website here. Progressive changes in estimated glomerular filtration rate (eGFR) were examined post-hoc in 166 patients with vitamin D insufficiency, SHPT and stage 3 or 4 CKD...

– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension – –Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm – – Ongoing Advance-HTN trial, first of two pivotal studies, will further characterize hypertensive endotype for enhanced response to lorundrostat treatment – RADNOR, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today presented a new...

IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — The following is Nymox’s response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company” or “Nymox”) warns its shareholders that false and manipulative behavior is involved in attempts to hold what the Company considers an unlawful, unauthorized, and improper “shareholders meeting” that does not have the support of the Company or anyone currently associated with the Company. Shareholders who are listed on Nymox’s proprietary shareholders list have been solicited and contacted by a proxy solicitation company in New York. That Company shareholder list is considered by the Company to be proprietary information that has been stolen by the individuals attempting to have this “shareholders meeting.” Those individuals...

TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) — Wallbridge Mining Company Limited (TSX:WM, OTCQX:WLBMF) (“Wallbridge” or the “Company”) is pleased to announce that it has completed the previously announced non-brokered private placement with Agnico Eagle Mines Limited (“Agnico”) of 7,926,277 common shares in the capital of the Company at a price of $0.11 per common share (the “Private Placement”). The Private Placement was undertaken pursuant to certain participation rights set out in a pre-existing participation agreement between the Company and a predecessor of Agnico. With the net proceeds from the Private Placement, together with the $9.4 million of gross proceeds from the flow through private placement that closed on October 26, 2023, the Company expects to have a year end cash balance of approximately $25 million, which it anticipates...

Icelandair introduces its flight schedule for 2024, the most extensive schedule to date. The Company will offer flights to over 50 destinations, with three connection banks within the day. and daily flights to 28 destinations in Europe and North America, with more than one flight a day to 19 destinations thereof. Halifax and Pittsburgh are new destinations in summer 2024 and frequency will be increased to a number of destinations. Increased connectivity will offer 800 different connections and far more through codeshare agreements with other airlines. In 2024, available seat kilometers (ASK) are expected to increase by at least 10% from the previous year.   Three Boeing 737 MAX 8 aircraft will be added to Icelandair’s fleet in 2024. The Company’s fleet will then consist of 42 aircraft, thereof 21 737 MAX.  Halifax and Pittsburg new destinations...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 02, 2023 (GLOBE NEWSWIRE) — Earthworks Industries Inc. (TSXV:EWK) (the “Company”) is pleased to announce that it has closed its previously announced commercially reasonable efforts private placement offering of an aggregate of 7,500,000 units (the “Units”) at a price of $0.20 per Unit (the “Issue Price”) for aggregate gross proceeds of $1,500,000 (the “Offering”). Each Unit consists of one common share in the capital of the Company (each, a “Common Share”) and one common share purchase warrant of the Company (each, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one additional Common Share at a price of C$0.40, subject to adjustment in certain events, at any time until November...